Oncology Archives - WuXi Biology

Mechanistic Profiling of ADC-resistant Cancer Cell Lines

Antibody-drug conjugates (ADCs) have emerged as an important modality in targeted cancer therapy development. However, acquired resistance continues to limit...

Unveiling Mechanisms of MRTX1133 Resistance

Recent years have seen major advances in KRAS G12D-targeted therapeutics. However, acquired drug resistance remains a significant clinical challenge, with...

Integrated Strategies for KRAS Inhibitor Development

As one of the most frequently mutated oncogenes in human cancers, KRAS was long considered an “undruggable” target. Recent landmark...

Development of the Venetoclax-Resistant AML Model

Acute myeloid leukemia (AML) remains a highly aggressive hematologic malignancy, responsible for over 100,000 deaths globally each year. The approval...

AACR 2026 Posters: Sneak Peek

AACR 2026 Posters | Sneak Peek The Annual Meeting of the American Association for Cancer Research (AACR) will be held...

Poster Presentations at AACR 2026

At AACR 2026, scientists from our WuXi Biology platform will present a collection of the company’s latest oncology research findings...

Supporting Discovery of mRNA Drugs

Unlike conventional protein-targeted therapies, which often provide only transient effects, nucleic acid therapeutics have the potential for long-lasting effects and...

mTOR Inhibition Enhances Targeted Protein Degradation Efficacy

Targeted protein degradation (TPD) approaches, including molecular glue degraders (MGDs) and proteolysis targeting chimeras (PROTACs), can overcome traditional occupancy-based inhibitor...